Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine (aTIV-1, Fluad), and versus an adjuvanted trivalent influenza vaccine (aTIV-2), containing the alternate B strain.
Epistemonikos ID: 57070e377895b66bb610846986fc7980a1e7cb76
First added on: May 21, 2024